English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
- ArriVent BioPharma, Inc. press release (NASDAQ:AVBP): FY net loss was $69.3 million.
- Research and development expenses were $64.9 million.
- General and administrative expenses were $9.7 million.
- As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $150.4 million.
More on ArriVent BioPharma
Read the full article here
